TLDR LINK is trading around $9.02–$9.10, down roughly 7% over the past two weeks but up about 1.8% in the last 24 hours. Price is consolidating in a tight rangeTLDR LINK is trading around $9.02–$9.10, down roughly 7% over the past two weeks but up about 1.8% in the last 24 hours. Price is consolidating in a tight range

Chainlink (LINK) Price: Testing Channel Support as Mastercard Deal and RWA Momentum Build

2026/06/01 15:17
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

TLDR

  • LINK is trading around $9.02–$9.10, down roughly 7% over the past two weeks but up about 1.8% in the last 24 hours.
  • Price is consolidating in a tight range between $8 and $10, with traders watching for a breakout toward $11.
  • Short-term technical indicators are bearish — LINK is below its 20-day moving average and showing a MACD crossover to the downside.
  • Mastercard has partnered with Chainlink to allow over 3.5 billion cardholders to buy crypto directly on-chain using traditional payment systems.
  • Analyst Ali Charts flagged $10.10 and $11 as key upside targets if buyers step in at current levels.

Chainlink’s native token LINK is trading in a narrow range near $9, caught between short-term bearish technicals and growing institutional interest in the protocol’s oracle infrastructure.

Chainlink (LINK) PriceChainlink (LINK) Price

At time of writing, LINK was changing hands at approximately $9.02 to $9.10, with a 24-hour trading volume of around $289–$315 million and a market cap of $6.56 billion.

The token posted a modest gain of about 1.8% in the most recent 24-hour period, but remains down close to 7% over the past two weeks, in line with broader market softness.

Crypto analyst Ali Charts posted on X that LINK is currently testing the bottom of its price channel. He said if buyers step in, he would be watching $10.10 and $11 as the next upside targets — levels that align with what other analysts are also watching.

The price action has been tightening into a narrow band, which technical analysts describe as compression. Trader and analyst World of Charts noted this kind of range-bound movement often signals that a larger move is building, though direction is not yet clear.

Bearish Signals in the Short Term

LINK is currently trading below its 20-day simple moving average of $9.57 and is approaching the lower Bollinger Band. The MACD line has crossed below its signal line and sits below the zero line — a setup that typically indicates sellers are in control in the near term.

Source: TradingView

A previous attempt to push toward $11 in May failed, and the price has since pulled back to the $9 area. The $8 to $10 range has acted as a holding zone for several months following a drop from $14 down to $7.30.

If the current support level fails to hold, analysts have flagged further consolidation or a retest of lower support levels as likely outcomes.

Mastercard Partnership Opens the Door for Billions of Users

On the fundamental side, Chainlink confirmed a partnership with Mastercard that would allow more than 3.5 billion Mastercard customers to buy crypto directly on-chain using their existing payment cards.

The integration connects Mastercard’s payment rails with Chainlink’s oracle protocol, removing the friction between fiat currency systems and blockchain transactions.

Chainlink acts as the secure data bridge that verifies real-world payment information and passes it to the blockchain. The tie-up is expected to simplify the onboarding process and make crypto purchases feel closer to a standard card transaction.

Chainlink’s broader value proposition centers on providing verified off-chain data to blockchain applications. Demand for that service is growing, particularly in real-world asset tokenization — where financial institutions need reliable data pipelines for things like treasury redemptions and fund tokenization.

The $10 level remains the key short-term target for bulls, with $11 the next level beyond that if momentum returns.

The post Chainlink (LINK) Price: Testing Channel Support as Mastercard Deal and RWA Momentum Build appeared first on CoinCentral.

Market Opportunity
Allo Logo
Allo Price(RWA)
$0.001544
$0.001544$0.001544
-2.95%
USD
Allo (RWA) Live Price Chart

SPACEX(PRE) Launchpad

SPACEX(PRE) LaunchpadSPACEX(PRE) Launchpad

Register for a chance to win a free lucky draw

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin is poised for a reversal if ETF demand returns or a ceasefire occurs, potentially crushing short sellers in a massive price squeeze.
Share
Coin Telegraph2026/04/04 19:58
Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Inertia is the invisible tax on modern industrial throughput. Every millisecond a robotic arm spends decelerating, or waiting for high-frequency vibrations to settle
Share
Techbullion2026/04/02 18:25

RealStocks Now Live

RealStocks Now LiveRealStocks Now Live

Trade real U.S. stock via regulated brokerage